MARKET

NVCR

NVCR

Novocure
NASDAQ
12.34
+0.29
+2.36%
After Hours: 12.36 +0.02 +0.16% 17:27 04/24 EDT
OPEN
12.09
PREV CLOSE
12.06
HIGH
12.39
LOW
12.02
VOLUME
1.31M
TURNOVER
0
52 WEEK HIGH
83.60
52 WEEK LOW
10.87
MARKET CAP
1.32B
P/E (TTM)
-6.3409
1D
5D
1M
3M
1Y
5Y
Results Of Novocure's METIS Phase 3 Clinical Trial For Patients With Brain Metastasis From Non-Small Cell Lung Cancer To Be Presented As Late-Breaking Abstract At ASCO 2024
The results of the METIS phase 3 clinical trial in brain metastases from non-small cell lung cancer (NSCLC) will be presented at the 2024 American Society of Clinical Oncology Annual Meeting in Chicago. METIS was a randomized trial of stereotactic radiosurgery with or without Tumor Treating Fields therapy for patients with 1-10 brain metastase from NSCLC. The METIS data will be present on June 3 as a late-breaking abstract.
Benzinga · 9h ago
Medpace (MEDP) Beats Q1 Earnings Estimates
NASDAQ · 2d ago
Analysts Anticipate ESML Will Reach $45
NASDAQ · 2d ago
Weekly Report: what happened at NVCR last week (0415-0419)?
Weekly Report · 2d ago
Weekly Report: what happened at NVCR last week (0408-0412)?
Weekly Report · 04/15 09:22
Commit To Buy NovoCure At $7.50, Earn 15.3% Using Options
NASDAQ · 04/12 15:34
Buy Rating on NovoCure: Promising METIS Therapy and Strategic Commercial Execution
TipRanks · 04/11 01:07
Novocure Price Target Raised to $28.00/Share From $25.00 by Piper Sandler
Dow Jones · 04/10 13:05
More
About NVCR
NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Webull offers Novocure Ltd stock information, including NASDAQ: NVCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVCR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NVCR stock methods without spending real money on the virtual paper trading platform.